Abstract: Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

Abstract: A method of conforming a periodic array to a surface is provided. The method comprises calculating, with a spatially-variant lattice algorithm, a pair of planar gratings across the surface, wherein the planar gratings are generated via reciprocal lattice vectors and summing the pair of planar gratings. Intersections produced by summing the gratings are scanned for maxima on the surface, and a periodic array of elements is located at the maxima on the surface. A normal vector is calculated at each maximum on the surface, and each element is rotated to match the direction of the respective normal vector at each maximum on the surface. The elements are then conformed to the surface via a shrink-wrap modifier operation.

Abstract: The present disclosure provides a new series of 8-hydroxyquinoline derivatives/analogs that are potent KDM4 inhibitors with high activity and selectivity against KDM4 enzymes. Also disclosed are the pharmaceutical compositions comprising such 8-hydroxyquinoline-based potent KDM4 inhibitors, or a pharmaceutically acceptable salt thereof, and method of use thereof, for treating cancer and neoplastic diseases and the like.

Abstract: An apparatus for monitoring a patient post operation having electrically conducting leads which are adapted to extend from inside the patient. The leads having electrodes adapted to communicate with a heart of the patient and apply electrical signals to the heart. The electrodes providing cardiac signals to the computer in response to the electrical signals so the computer can determine in real time at least one of heart volume, end diastolic heart volume, end systolic heart volume, stroke volume, change in heart volume, change in stroke volume, contractility, respiration rate or tidal volume regarding the patient.

Abstract: Described herein are dry powder inhalation mixtures for pulmonary delivery and processes for making the same. A process for making a dry powder inhaler blend as described herein comprises introducing an active pharmaceutical ingredient, a lubricant, and a carrier into a multi-screw extruder; and continuously mixing the active pharmaceutical ingredient, the lubricant, and the carrier in the multi-screw extruder to form a dry powder inhaler blend. In this method, the active pharmaceutical ingredient, the lubricant, and the carrier are in the form of a powder.

Abstract: An embodiment includes an apparatus for coupling a user to a robot to provide robot-assisted physical therapy to the user. Other embodiments are described herein.

Abstract: The present disclosure relates to degradable polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and have backbones which are capable of undergoing degradation in vivo. In some aspects, the disclosure also provides methods of using these degradable polymers for the delivery of a drug.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.

Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).

Abstract: The present invention includes a method and kit for single-primer tiled sequencing comprising: reverse transcribing a target nucleic acid with multiple tiled primers spaced along the genome, each only targeting one annealing site to form amplicons in the presence of terminating 3? azido nucleotides to incorporate the terminating 3? azido nucleotides into the cDNA; click-ligating a downstream primer onto tire 3? azido terminated cDNA such that a second template-specific primer is not required; amplifying the click-ligated cDNA; and sequencing the amplicons.

Abstract: The invention generally relates to the development of immunogenic compositions comprising a DNA copy of at least one live attenuated plus-sense single-stranded RNA virus genome, such as the genome of a live-attenuated Zika vims (ZIKV), Japanese encephalitis virus (JEV) or yellow fever vims (YFV). The immunogenic compositions can be used for treating or conferring protective immunity against diseases related to plus-sense single-stranded RNA viruses, e.g. for affording prolonged immunoprotection against such viruses and protective immunity is conferred at low diseases, e.g., as low as 300 or 500 ng after administration of a single pLAV dosage.

Abstract: Disclosed are techniques for initiating and sustaining a transport barrier within a magnetically confined plasma in a plasma fusion device. For a toroidal magnetic configuration, a characteristic region of the magnetic field can be established by generating a current within the plasma or by other means. The location of the characteristic region can be controlled to be suitably close to the interior walls of the plasma fusion device to allow a quantity of particles to be injected into the plasma at or inside the characteristic region. The quantity of particles can augment the density of the plasma and create a density gradient within the characteristic region, resulting in the formation of a transport barrier at or inside the characteristic region.

Abstract: Embodiments of the disclosure concern devices comprised of resorbable, shape-memory foam configured to allow for healing at a desired location. In particular embodiments, use of the device at the location utilizes the inherent environment at the location to allow expansion of the device, resulting in an improved fit for the device. In specific cases, the device is a vaginal stent configured for use for pediatric or adolescent populations.

Abstract: Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.

Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.

Abstract: Disclosed herein are methods of synthesizing compounds of the formula wherein the variables are defined herein. Also provided are compounds produced using these methods. In some aspects, the methods provided herein may be used to create di- and tri-substituted BCPs.

Abstract: Photoactivatable nanoparticles for simultaneous PD-L1 immune checkpoint targeting and blocking are capable of modulating tumor stroma, promoting self-delivery, improving tumor growth inhibition, and improving survival outcomes even with just a single priming dose. Light activation of the nanoparticles disrupts tumor collagen, reduces tumor fibroblasts, and promotes their self-delivery in vitro and in vivo which correlates with overall survival in mice. This demonstrates their ability to overcome the most significant barrier in nanoparticle delivery in PDAC tumors.

Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.

Abstract: Various embodiments of the present technology provide a novel deep learning-based error correction coding scheme for AWGN channels under the constraint of moderate to low bit quantization (e.g., one-bit quantization) in the receiver. Some embodiments of the error correction code minimize the probability of bit error can be obtained by perfectly training a special autoencoder, in which “perfectly” refers to finding the global minima of its cost function. However, perfect training is not possible in most cases. To approach the performance of a perfectly trained autoencoder with a suboptimum training, some embodiments utilize turbo codes as an implicit regularization, i.e., using a concatenation of a turbo code and an autoencoder.